Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Current Investments: 2021-2024

Historic Cash & Current Investments for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $597.5 million.

  • Krystal Biotech's Cash & Current Investments rose 24.26% to $731.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 18.44%. This contributed to the annual value of $597.5 million for FY2024, which is 12.28% up from last year.
  • Krystal Biotech's Cash & Current Investments amounted to $597.5 million in FY2024, which was up 12.28% from $532.2 million recorded in FY2023.
  • Krystal Biotech's Cash & Current Investments' 5-year high stood at $597.5 million during FY2024, with a 5-year trough of $379.2 million in FY2022.
  • In the last 3 years, Krystal Biotech's Cash & Current Investments had a median value of $532.2 million in 2023 and averaged $503.0 million.
  • In the last 5 years, Krystal Biotech's Cash & Current Investments declined by 13.45% in 2022 and then surged by 40.35% in 2023.
  • Over the past 4 years, Krystal Biotech's Cash & Current Investments (Yearly) stood at $438.1 million in 2021, then decreased by 13.45% to $379.2 million in 2022, then skyrocketed by 40.35% to $532.2 million in 2023, then increased by 12.28% to $597.5 million in 2024.